[Deutivacaftor/tezacaftor/vanzacaftor (cystic fibrosis, at least one non-Class I mutation, >= 6 years) – Benefit assessment according to §35a Social Code Book V]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018016133
German
Original Title: Deutivacaftor/Tezacaftor/Vanzacaftor (Zystische Fibrose, mindestens 1 Nicht-Klasse-I-Mutation, ≥ 6 Jahre) – Nutzenbewertung gemäß § 35a SGB V
Details
Project Status: Completed
Year Published: 2026
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Cystic Fibrosis
  • Child
  • Adolescent
  • Adult
  • Drug Combinations
  • Cystic Fibrosis Transmembrane Conductance Regulator
  • Aminophenols
  • Chloride Channel Agonists
  • Indoles
  • Pyrazoles
  • Pyridines
  • Pyrrolidines
  • Quinolones
Keywords
  • Deutivacaftor
  • Tezacaftor
  • Vanzacaftor
  • Cystic Fibrosis
  • Child
  • Adolescent
  • Adult
  • Benefit Assessment
  • NCT05033080
  • NCT05076149
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.